Carregant...

The Albumin in Acute Stroke (ALIAS) Part 1 Trial: An exploratory efficacy analysis

BACKGROUND: The ALIAS Part 2 Trial is directly testing whether 2g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hill, Michael D., Martin, Renee, Palesch, Yuko, Tamariz, Diego, Ryckborst, Karla J., Moy, Claudia S., Barsan, William G., Ginsberg, Myron D.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3118599/
https://ncbi.nlm.nih.gov/pubmed/21546491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.610980
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!